Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy and safety results for Dapirolizumab Pegol in moderately to severely active Systemic Lupus Erythematosus; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Dapirolizumab Pegol (dapirolizumab pegol)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2025-04-24